论文部分内容阅读
恶性疟原虫对抗疟药抗性的增长需要认真对待,以确保制定合理的国家药物政策。要获得对一个国家或地区抗性模式的总体认识需要多点的合作试验。为促进此进程必须使各个疟疾治疗试验的结果具可比性。近期在《英国皇家热带医学与卫生学杂志》上连续发表的文章已证明了此原则的重要性。由同一医院的研究者们用不同的方法进行了两组试验。Falade等在第一组试验中比较了卤泛曲林、乙胺嘧啶/磺胺多辛与氯喹的疗效。病例入选标准为恶性疟原虫血密度高于1000/μl,就诊前24小时内有发热史。开始治疗后7天评价寄生虫学治愈率;虫血密度通过计数
The increased resistance of Plasmodium falciparum to anti-malarial drugs needs to be taken seriously to ensure a sound national drug policy. Getting a general understanding of the resistance patterns in a country requires more collaborative experimentation. To facilitate this process, the results of individual malaria treatment trials must be comparable. A recent series of articles published in the British Journal of Tropical Medicine and Hygiene has demonstrated the importance of this principle. Two groups of tests were conducted by different methods by researchers in the same hospital. Falade et al compared the efficacy of halibutramine, pyrimethamine / sulfadoxine with chloroquine in the first group of trials. Case selection criteria for the blood density of Plasmodium falciparum is higher than 1000 / μl, fever within 24 hours before treatment. Seven days after initiation of treatment, the parasitological cure rate was evaluated; the worm blood density was counted